DSM-Firmenich Ltd

DSFIR

Equity

ISIN CH1216478797 / Valor 121647879

Euronext - Euronext Amsterdam (2024-12-23)

EUR 97.42-0.47%

DSM-Firmenich Ltd
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

DSM-Firmenich Ltd is a company that recently completed the sale and transfer of its equity interest in DSM Jiangshan Pharmaceutical Co., Ltd. to Jingjiang Cosfocus Health Technology Co., Ltd. Additionally, the company has announced plans to repurchase 1,500,000 ordinary shares to cover commitments under its share-based compensation plans starting April 8, 2024. This move reflects the company's strategic focus on optimizing its business operations and ensuring financial stability.

Summarized from source with an LLMView SourceSector: Industrials

Sales Growth

In the first half of 2024, DSM-Firmenich Ltd reported sales of €6,298 million, marking a 2% increase compared to the pro forma H1 2023 sales of €6,152 million. The company experienced organic sales growth of 4% during this period.

Adjusted EBITDA

DSM-Firmenich Ltd achieved an Adjusted EBITDA of €976 million in H1 2024, reflecting a 5% increase from the pro forma H1 2023 figure of €929 million. The Adjusted EBITDA margin improved slightly to 15.5% from 15.1% in the previous year.

Net Profit

The net profit for DSM-Firmenich Ltd in H1 2024 was €50 million, a significant decrease from the €2,375 million reported in H1 2023 on an IFRS basis. This decline is attributed to various strategic and operational changes within the company.

Divisional Performance

In H1 2024, the Perfumery & Beauty division reported sales of €2,007 million, a 7% increase from the previous year. The Taste, Texture & Health division also saw a 6% rise in sales, reaching €1,632 million. However, the Health, Nutrition & Care division experienced a 5% decline in sales.

2024 Outlook

DSM-Firmenich Ltd has increased its full-year 2024 outlook, expecting an Adjusted EBITDA of around €2 billion. This optimistic forecast is based on positive business momentum and the anticipated benefits from synergy delivery and the vitamin transformation program.

Summarized from source with an LLMView Source

Key figures

6.55%1Y

%3Y

%5Y

Performance

24.7%1Y

26.0%3Y

26.0%5Y

Volatility